10-Q: Apyx Medical Narrows Q2 Loss, Launches AYON System

Apyx Medical Corporation reported a significant reduction in net loss for Q2 2025, driven by substantial cost-cutting measures, despite a slight revenue decline, and announced the commercial launch of its AYON Body Contouring System.

Summary

• Apyx Medical Corporation reported a net loss of $3.738 million for the three months ended June 30, 2025, a significant improvement from a net loss of $6.586 million for the same period in 2024.
• For the six months ended June 30, 2025, the net loss was $7.910 million, compared to $14.176 million for the prior year period.
• Total sales decreased by 6.4% to $11.373 million for the three months ended June 30, 2025, and by 7.1% to $20.803 million for the six months ended June 30, 2025, compared to the respective prior year periods.
• The Advanced Energy segment's sales decreased by 1.0% in Q2 2025 but increased by 2.0% for the six-month period, while OEM segment sales significantly decreased by 28.5% in Q2 2025 and 37.3% for the six-month period.
• Gross profit decreased by 5.5% to $7.083 million in Q2 2025, but gross margin improved to 62.3% from 61.7% in the prior year quarter, primarily due to product mix.
• Total other costs and expenses decreased substantially by 26.0% in Q2 2025 and 28.3% for the six-month period, driven by reductions in salaries and related costs, R&D, and professional services.
• Cash and cash equivalents stood at $29.301 million as of June 30, 2025, down from $31.741 million at December 31, 2024.
• Net cash used in operating activities significantly improved, decreasing to $1.935 million for the six months ended June 30, 2025, from $10.670 million in the prior year period.
• The company received 510(k) clearance from the FDA for its AYON Body Contouring System on May 13, 2025, with commercial launch planned for the second half of 2025.
• Cost-saving initiatives implemented in November 2024, including a 25% reduction in the US workforce, are expected to result in annualized savings of approximately $4.3 million and reduce annual operating expenses below $40 million in fiscal 2025.
• The company remains in compliance with financial covenants under its Perceptive Credit Agreement as of June 30, 2025.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While the company continues to incur net losses and cash outflows, the significant reduction in losses and operating expenses, coupled with improved cash flow from operations, indicates effective cost control and a positive trajectory. The FDA clearance and upcoming commercial launch of the AYON system also provide a strong growth catalyst. However, ongoing product liability litigation, a decline in overall sales, and the need for potential future financing temper the overall sentiment.

Positives

• Net loss significantly reduced for both the three and six months ended June 30, 2025, compared to the prior year periods, indicating improved financial performance.
• Operating loss improved substantially, decreasing from $(5.547) million to $(2.574) million in Q2 2025 and from $(12.162) million to $(5.625) million for the six-month period.
• Gross margin increased to 62.3% in Q2 2025 (from 61.7%) and to 61.3% for the six-month period (from 60.0%), driven by favorable product mix.
• Total other costs and expenses decreased significantly by 26.0% in Q2 2025 and 28.3% for the six-month period, demonstrating effective cost control measures.
• Received 510(k) clearance from the U.S. FDA for the AYON Body Contouring System on May 13, 2025, expanding product offerings and market potential.
• Commercial launch of the AYON system is planned for the second half of 2025, with pre-orders already taken in Q2 2025.
• Implemented cost-saving restructuring in November 2024, including a 25% reduction in the US workforce, expected to yield $4.3 million in annualized savings.
• Anticipates reducing annual operating expenses below $40 million in fiscal 2025 due to identified cost savings.
• Net cash used in operating activities improved significantly, decreasing from $10.670 million in H1 2024 to $1.935 million in H1 2025.
• Maintained compliance with all financial covenants under the Perceptive Credit Agreement as of June 30, 2025.

Negatives

• Continued to incur recurring net losses and cash outflows from operations, with a net loss of $3.738 million in Q2 2025 and $7.910 million for H1 2025.
• Total sales decreased by 6.4% in Q2 2025 and 7.1% for H1 2025 compared to the prior year periods.
• OEM segment sales experienced a significant decline of 28.5% in Q2 2025 and 37.3% for H1 2025 due to decreased sales volume to existing customers.
• Cash and cash equivalents decreased by $2.440 million from December 31, 2024, to June 30, 2025.
• Accumulated deficit increased to $85.839 million as of June 30, 2025, from $77.911 million at December 31, 2024.
• Involved in multiple product liability lawsuits related to its Helium Plasma Platform Technology, with potential for costs to exceed insurance coverage.
• Acknowledged an initial negative impact on the plastic and cosmetic surgery market due to the increased use of GLP-1 weight loss drugs.

Risks

• Continued recurring net losses and cash outflows from operations are anticipated in the near term.
• Uncertainty regarding the availability and terms of additional equity and/or debt financing, which may be necessary to fund operations and capital needs.
• Potential for dilution to stockholders if additional equity financing is pursued.
• Risk of further debt service obligations and restrictive covenants if additional debt financing is incurred.
• Inability to raise sufficient capital could lead to delays, limitations, reductions, or termination of sales, marketing, and product development activities.
• Ongoing product liability litigation related to Helium Plasma Platform Technology, with potential for damages to exceed aggregate insurance coverage limits or for insurance carriers to disclaim coverage, leading to material adverse financial impact.
• The impact of GLP-1 receptor agonists on the aesthetic market, while potentially creating a 'tailwind' for Renuvion, initially caused uncertainty and a negative impact on plastic and cosmetic surgeons' revenue.
• Uncertainty regarding the overall impact of trade policy and tariffs, including potential retaliatory measures, inflationary effects, and reduced cost competitiveness of products.
• Inflationary pressures on raw materials, freight, and labor costs could adversely impact future financial performance.

Future Outlook

The company anticipates continued losses in the near term but plans to fund operations through existing cash, product sales, and potentially additional equity or debt financing. It expects the commercial launch of the AYON Body Contouring System in the second half of 2025 and plans an additional 510(k) submission for power liposuction later this year. Management foresees that implemented cost savings will reduce annual operating expenses below $40 million in fiscal 2025 and believes that the increased use of GLP-1s, while initially disruptive, will ultimately drive demand for Renuvion products by addressing loose skin resulting from rapid weight loss.

Management Comments

• We believe the increased use of GLP-1s had an initial negative impact on the revenue for plastic and cosmetic surgeons and created uncertainty in the aesthetic space. However, we believe, that the use of these drugs will have a ripple effect which will drive people towards plastic surgery and may provide a tailwind for sales of our Renuvion products.
• Renuvion is the only FDA approved device for the treatment of loose skin post liposuction.
• We are actively preparing for a commercial launch of AYON leveraging our relationships with key surgeons in critical geographies. The official commercial launch of AYON will commence in the second half of 2025.
• We estimate the annualized future cost savings from the reduction in force to be approximately $4.3 million which we expect to contribute to our goal of decreasing loss and achieving cash-flow breakeven.
• We foresee, in totality, these cost savings will reduce our annual operating expenses below $40 million in 2025.

Industry Context

The aesthetic surgery market is currently experiencing a dynamic shift due to the rising popularity of GLP-1 receptor agonists (e.g., Mounjaro, Wegovy, Ozempic) for weight loss. While these drugs initially caused uncertainty and a negative impact on plastic and cosmetic surgeons' revenue, Apyx Medical anticipates a 'ripple effect' where rapid weight loss leads to loose skin, thereby increasing demand for body contouring procedures like those performed with Renuvion. Renuvion's unique FDA clearance for post-liposuction skin laxity positions it favorably to capitalize on this emerging need, potentially expanding its total available market.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• Involved in multiple legal actions related to the use of its Helium Plasma Platform Technology (Renuvion), which are being defended by the company's insurance carrier-appointed counsel.
• Two related product liability cases from 2022, involving 10 individual plaintiffs, with two claims dismissed in March 2024. Estimated loss for defense costs is approximately $1.65 million to $1.95 million, with $1.45 million accrued in 2022 and $0.2 million in 2024.
• Named as a defendant in multiple product liability lawsuits filed in March 2024, alleging off-label use and mismarketing of Renuvion products prior to 2023 FDA 510(k) clearance. Estimated loss for defense costs is between $1.3 million and $1.5 million, with $1.3 million accrued in 2024.
• The company denies liability and intends to vigorously defend these suits, but acknowledges that costs could have a material adverse impact if damages exceed aggregate insurance coverage limits or if insurance carriers disclaim coverage.

Related Party Transactions

• Purchases from the China JV partner (supplier) amounted to approximately $341,000 for the three months ended June 30, 2025, and $370,000 for the six months ended June 30, 2025.
• Net payables to this supplier were approximately $489,000 at June 30, 2025, compared to $243,000 at December 31, 2024.
• Two relatives of Nikolay Shilev, Apyx Bulgaria's Managing Director, are employees of the company (Teodora Shileva in accounting, Svetoslav Shilev as quality manager).

Stakeholder Impact

• Shareholders: Potential for dilution if additional equity financing is pursued; benefit from reduced net losses and improved operational efficiency.
• Employees: Experienced a 25% reduction in the US workforce in November 2024 as part of cost-saving measures.
• Customers: Will benefit from the commercial launch of the new AYON Body Contouring System, expanding treatment options.
• Creditors: The company's compliance with debt covenants under the Perceptive Credit Agreement provides reassurance, but continued recurring losses and the need for future financing remain relevant.
• Suppliers: The company has purchase commitments totaling approximately $3.6 million, indicating ongoing business relationships.

Next Steps

• Commence official commercial launch of the AYON Body Contouring System in the second half of 2025.
• Plan an additional 510(k) submission for AYON to include power liposuction later this year.
• Continue to implement identified cost savings to reduce annual operating expenses below $40 million in fiscal 2025.
• Actively monitor trade policy and tariff announcements and their potential impact on business.

Key Dates

Recommendation

While Apyx Medical Corporation demonstrated significant improvements in reducing net losses and operating cash outflows due to effective cost-cutting measures, and secured FDA clearance for its new AYON system, the company still faces recurring net losses and a decline in overall revenue, particularly in its OEM segment. The ongoing product liability litigation presents a material risk, and the need for potential future capital raises could lead to shareholder dilution. The positive outlook for the AYON launch and the potential 'tailwind' from GLP-1s are encouraging, but the company's financial position is not yet robust enough to warrant a 'buy' recommendation, nor are the challenges severe enough to suggest a 'sell' given the operational improvements. A 'hold' recommendation is appropriate as the company navigates its strategic initiatives and aims for cash-flow breakeven.

Keywords

Apyx Medical, Medical Devices, Aesthetic Surgery, Body Contouring, Renuvion, J-Plasma, AYON System, FDA Clearance, SEC Filing, Quarterly Report, Financial Results, Cost Savings, Helium Plasma Technology, OEM, Product Liability, GLP-1